A reversible gut sleeve could offer a new way to treat obesity

NCT ID NCT07675122

Disease control Sponsor: Chinese University of Hong Kong Source: ClinicalTrials.gov ↗

First seen Jun 30, 2026 · Last updated Sep 16, 2026 · Updated 3 times

Summary

This pilot study tests a temporary, flexible tube called a duodenal-jejunal bypass sleeve. It is placed in the upper intestine using an endoscope and left for 3 months to help with weight loss and improve metabolic syndrome. The study involves 20 adults with obesity or excess weight plus metabolic syndrome. Researchers will measure weight loss, body fat changes, and safety over 12 months.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: duodenal-jejunal bypass sleeve
What this could lead to: If successful, this could offer a less invasive, reversible alternative to gastric bypass surgery for weight loss and metabolic syndrome.
What could go wrong: This is a small pilot study with only 20 participants, so results may not apply broadly. The sleeve is temporary (3 months) and long-term benefits are unknown.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 20 people

The number the study aims to enrol. It can still change while the study runs.

Expected to start

Sep 2026

An estimate. Start dates often move.

Expected to finish

Jul 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Body mass index (BMI) ≥27.5kg/m2; or BMI ≥25 kg/m2 with metabolic syndrome Exclusion Criteria: * Patients who have lost more than 5 kg of weight in the past three months * Patients who have used glucagon-like peptide-1 receptor agonists (GLP-1RAs) in the past three months * Patients who are currently taking weight loss drugs such as orlistat * Those who have taken antiplatelet drugs or anticoagulant drugs such as aspirin in the past month * iron deficiency or iron deficiency anemia * Gastrointestinal malformations, such as patients with gastrointestinal atresia or other patients who will cause gastrointestinal implantation failure * Those with a history of cholecystitis and liver abscess * There is a known infection, and the type of disease and the severity of the infection are not suitable for use by clinicians * coagulation dysfunction; * Severe liver and kidney dysfunction, AST /ALT \> 2.5 times, total bilirubin \> 35 μmol/L, blood creatinine concentration greater than 180 μmol/L * Patients with ASA IV \& V * Drug or alcohol abuse addiction or suffering from uncontrollable mental illness * Duodenal bulb ulcer, gastric ulcer or previous and existing pancreatitis * Coronary heart disease, angina, cardiac function grade III or above, or pulmonary dysfunction * Patients who have undergone ERCP before * Patients with potential bleeding or telangiectasia in the stomach, esophagus, small intestine and other parts * Have a history of systemic lupus erythematosus, scleroderma * Those who have contraindications to endoscopy (judged by clinicians) * Pregnant women or those who are preparing to become pregnant * Those who are allergic to nickel-titanium * Any other situation that the clinician deems unsuitable for participation in this product

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Metabolic syndrome (METS) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

abdominal obesity-metabolic syndrome metabolic syndrome X Obesity obesity disorder

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Metabolic syndrome (METS) Obesity

How to take part

Only the study team decides who joins. These are the ways to reach them.

The places running it

2 sites. The list below names each one and where it is.
The official record

ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

Open the record ↗
A doctor treating you

A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

A reversible gut sleeve could offer a new way to treat obesity

What the study statuses mean